Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CONVINCE

Financiado

Cerrado

The Comparison of High Dose Heamodiafiltration HDF versus Haemodialyse

End stage kidney disease ranks among the most severe chronic non-communicable diseases with an unmet medical need, given the high (between 10 and 15%) and stable annual mortality rates. Kidney replacement therapy is necessary when... ver más

31/12/2023

UMC UTRECHT

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-12-31

SC1-PM-10-2017: Comparing the effectiveness of exis...

I+D

Cerrada hace 8 años

0% 97% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

UMC UTRECHT

774.81K€ | Lider

UNIVERSITY COLLEGE LONDON

200.00K€ | Participante

UNIBA

9.69K€ | Participante

FMC

949.68K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ROAR Role of endocycle in Acute Kidney Injury Response and Chroni... 171K€ Cerrado

RTC2019-007197-1 Desarrollo preclínico de una nueva terapia celular para el t... 283K€ Cerrado

SAF2014-59945-R DIANAS DEPENDIENTES DE ANDROGENOS INVOLUCRADAS EN PROCESOS D... 230K€ Cerrado

EUIN2013-51079 RED EUROPEA PARA EL ESTUDIO DEL FRACASO RENAL AGUDO 13K€ Cerrado

STAR-T REK Set up and comparison of multiple stem cell approaches for k... 4M€ Cerrado

RENALSTEM Developing a stem cell based therapy to replace nephrons los... 168K€ Cerrado

Duración del proyecto: 72 meses Fecha Inicio: 2017-12-05
Fecha Fin: 2023-12-31

Líder del proyecto

UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto End stage kidney disease ranks among the most severe chronic non-communicable diseases with an unmet medical need, given the high (between 10 and 15%) and stable annual mortality rates. Kidney replacement therapy is necessary when kidney function is below 10% of the normal value. Much effort is put into developing strategies to prevent chronic kidney disease progression. Regenerative medicine still is in the experimental phase and kidney transplantation is only available for a small number of patients. Indeed, the everyday reality is the growing number of dialysis patients. Haemodialysis treatment is the current standard of care for the vast majority of patients with end stage kidney disease. It is a substantial burden to the patient and for society. Haemodialysis treatment is associated with high risks for fatal and non-fatal cardiovascular disease, for infections, hospitalisation and low quality of life. Improvement in the currently available standard is urgently needed. Over the past decade an alternative for haemodialysis became available, i.e. haemodiafiltration. Both are accepted by regulatory authorities. Haemodiafiltration removes waste products that are accumulated due to kidney failure, more effecticvely than standard hemodialysis. Present evidence supports the idea of superiority of haemodialfiltration compared to standard haemodialysis. However, definite proof is lacking and as a consequence haemodiafiltration is not yet widely applied. This consortium aims to determine the best possible dialysis treatment by comparing the conventional guideline based haemodialysis treatment versus high-dose haemodiafiltration by carrying out a prospective randomized controlled clinical trial addressing clinical endpoints, quality of life and a cost-utility analysis. The study will deliver an answer on the question which intervention gives the best value for money. Therefore, it will be considered a land mark study, allowing to publish an end of discussion paper

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores